The proline-rich Akt substrate of 40 kDa (PRAS40) protein is not only a substrate of the protein kinase Akt but also a component of the mTOR complex 1 (mTORC1), thus it links the Akt and the mTOR pathways. We investigated the potential protective role of PRAS40 in cerebral ischemia and its underlying mechanisms by using rats with lentiviral over-expression of PRAS40 and mice with PRAS40 gene knockout (PRAS40 KO). Our results show that gene transfer of PRAS40 reduced infarction size in rats by promoting phosphorylation of Akt, FKHR (FOXO1), PRAS40, and mTOR. In contrast, PRAS40 KO increased infarction size. Although the PRAS40 KO under normal condition did not alter baseline levels of phosphorylated proteins in the Akt and mTOR pathways, PRAS40 KO that underwent stroke exhibited reduced protein levels of p-S6K and p-S6 in the mTOR pathway but not p-Akt, or p-PTEN in the Akt pathway. Furthermore, co-immunoprecipitation suggests that there were less interactive effects between Akt and mTOR in the PRAS40 KO. In conclusion, PRAS40 appears to reduce brain injury by converting cell signaling from Akt to mTOR.
Introduction
The proline-rich Akt substrate of 40-kDa (PRAS40) protein was first identified as a 14-3-3 binding protein and substrate of Akt in the Roth laboratory 10 years ago (Kovacina et al., 2003) . Later it was found that PRAS40 is also an important component and a substrate of the mammalian target of rapamycin complex 1 (mTORC1) (Wang et al., 2007) . Thus, PRAS40 is an interactive linker between the Akt and mTOR pathways.
Both the Akt (Zhao et al., 2006) and mTOR pathways (Guertin and Sabatini, 2005, 2007) play protective roles against brain injury induced by stroke. Akt has long been known to contribute to neuronal survival after stroke (Gao et al., 2008; Noshita et al., 2003; Ouyang et al., 1999; Zhao et al., 2005) . Recently, the involvement of the mTOR pathway has also been reported, as several neuroprotectants have been shown to inhibit infarction by upregulating mTOR activity (Koh, 2008; Koh et al., 2008; Wu et al., 2012) . In alignment with the roles of Akt and mTOR, PRAS40 also appears to attenuate cerebral ischemic injury after stroke (Saito et al., 2004 (Saito et al., , 2006 . Previous studies from the Chan laboratory have found that stroke reduces phosphorylated PRAS40 (p-PRAS40), and decreases binding of p-PRAS40 to phosphorylated Akt (p-Akt) and the 14-3-3 protein (Saito et al., 2004 (Saito et al., , 2006 , suggesting that PRAS40 is involved in brain injury induced by stroke. More importantly, liposome-mediated p-PRAS40 cDNA transfection inhibits apoptotic neuronal cell death, suggesting that PRAS40 overexpression is neuroprotective (Saito et al., 2004) .
Most recently, we reported that lentiviral vector gene transfer of the Akt isoforms Akt1 and Akt3 attenuated brain injury by promoting both p-PRAS40 and p-mTOR protein levels, and mTOR inhibition by rapamycin abolished the protective effects Akt1 and Akt3 gene transfer (Xie et al., 2013a) . Our results suggest that a close relationship exists between Akt and mTOR in their protection against stroke, and that PRAS40 may serve a pivotal role (Xie et al., 2013a) . Nevertheless, many questions remain about how PRAS40 functions in cerebral ischemia. First, the underlying protective mechanisms of PRAS40 against stroke remain elusive, such as how PRAS40 affects Akt and mTOR activity and how they interact. Second, previously reported protective effects of PRAS40 against stroke were demonstrated using liposome-mediated PRAS40 gene transfer, which is considered to have insufficient gene transfer efficacy for neurons in vivo, and this protective effect has not been confirmed with more efficient gene transfer techniques, such as lentiviral vector systems. Third, previous studies have suggested that overexpression of PRAS40 inhibits, while knockdown of PRAS40 promotes, mTOR activity 
